Eupraxia Pharmaceuticals Inc. (EPRX)
EPRX Stock Price Chart
Explore Eupraxia Pharmaceuticals Inc. interactive price chart. Choose custom timeframes to analyze EPRX price movements and trends.
EPRX Company Profile
Discover essential business fundamentals and corporate details for Eupraxia Pharmaceuticals Inc. (EPRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
—
Employees
33.00
Website
https://www.eupraxiapharma.comCEO
James A. Helliwell FRCPC,
Description
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
EPRX Financial Timeline
Browse a chronological timeline of Eupraxia Pharmaceuticals Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.22.
Earnings released on 12 Aug 2025
EPS came in at -$0.26 falling short of the estimated -$0.21 by -23.81%.
Earnings released on 6 May 2025
EPS came in at -$0.21 falling short of the estimated -$0.19 by -10.53%.
Earnings released on 20 Mar 2025
EPS came in at -$0.21 falling short of the estimated -$0.18 by -16.67%.
Earnings released on 7 Nov 2024
EPS came in at -$0.17 falling short of the estimated -$0.13 by -30.05%.
Earnings released on 7 Aug 2024
EPS came in at -$0.17 falling short of the estimated -$0.17 by -0.37%.
Earnings released on 8 May 2024
EPS came in at -$0.21 falling short of the estimated -$0.17 by -23.25%.
Earnings released on 21 Mar 2024
EPS came in at -$0.15 , while revenue for the quarter reached $2.98M .
Earnings released on 30 Sept 2023
EPS came in at -$0.25 falling short of the estimated -$0.11 by -124.05%.
Earnings released on 30 Jun 2023
EPS came in at -$0.36 falling short of the estimated -$0.27 by -30.95%.
Earnings released on 31 Mar 2023
EPS came in at -$0.23 falling short of the estimated -$0.17 by -34.38%.
Earnings released on 31 Dec 2022
EPS came in at -$0.41 falling short of the estimated -$0.13 by -225.81%.
Earnings released on 30 Sept 2022
EPS came in at -$0.22 surpassing the estimated -$0.31 by +29.96%.
Earnings released on 30 Jun 2022
EPS came in at -$0.31 falling short of the estimated -$0.30 by -3.72%.
Earnings released on 31 Mar 2022
EPS came in at -$0.26 .
Earnings released on 31 Dec 2021
EPS came in at -$0.30 falling short of the estimated -$0.27 by -10.30%.
Earnings released on 30 Sept 2021
EPS came in at -$0.35 .
Earnings released on 30 Jun 2021
EPS came in at -$0.41 .
Earnings released on 31 Mar 2021
EPS came in at -$1.13 .
Earnings released on 31 Dec 2020
EPS came in at -$0.01 .
Earnings released on 30 Sept 2020
EPS came in at -$0.08 .
EPRX Stock Performance
Access detailed EPRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.